| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1090...
Citigroup analyst Peter Verdult maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1250 to $1500.
Blue-chip stocks hit record highs as investors rotate toward old-economy leaders; AMD surges, gold rallies, oil slides on OPEC ...
- Reuters Citing UBS Healthcare Conf
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India t...
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready ...
https://www.bloomberg.com/news/articles/2025-11-12/lilly-drops-cvs-drug-plan-for-workers-after-novo-obesity-deal